New antibody prevents recurrence of Clostridium difficile infection

Zinplava (bezlotoxumab) is a human monoclonal antibody indicated for the prevention of recurrence of Clostridum difficile infection (CDI) in adults at high risk of recurrence.

Zinplava is not a treatment for CDI and has no effect on the current CDI episode. | SCIENCE PHOTO LIBRARY
Zinplava is not a treatment for CDI and has no effect on the current CDI episode. | SCIENCE PHOTO LIBRARY

Zinplava should be administered as a single intravenous infusion of 10mg/kg given over 60 minutes during the initial 10 to 14 days of the course of antibacterial therapy for CDI. Zinplava is not a treatment for CDI and has no effect on the current CDI episode.

Antitoxin antibody

Bezlotoxumab is a human monoclonal antibody that binds with high affinity to C. difficile toxin B and neutralises its activity. CDI recurrence is prevented through the provision of passive immunity against toxin produced by the outgrowth of persistent or newly-acquired C. difficile spores.

Recurrence rates

The efficacy of bezlotoxumab was evaluated in the MODIFY I and MODIFY II trials in 1613 adults with a confirmed diagnosis of CDI treated with a 10- to 14-day course of oral antibacterial therapy. Patients were randomised to receive a single infusion of bezlotoxumab or placebo within the first 14 days of antibacterial therapy (median, day 3).

Among the patients included in the full analysis set (bezlotoxumab, n=781; placebo, n=773), the CDI recurrence rate within 12 weeks of the infusion was significantly lower in those who received bezlotoxumab than in those who received placebo (16.5% vs 26.6%, p<0.0001). The clinical cure rates of the presenting CDI episode were comparable between the two groups.

Secondary analysis of the results did not point towards a benefit of Zinplava in patients with no known risk factors for CDI.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases